Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.

ABSTRACT:

Background

The phase 3 CALGB 90203 (Alliance) trial evaluated neoadjuvant chemohormonal therapy for high-risk localized prostate cancer before radical prostatectomy. We dissected the molecular features of post-treated tumors with long-term clinical outcomes to explore mechanisms of response and resistance to chemohormonal therapy.

Methods

We evaluated 471 radical prostatectomy tumors, including 294 samples from 166 patients treated with 6 cycles of docetaxel plus androgen deprivation therapy before radical prostatectomy and 177 samples from 97 patients in the control arm (radical prostatectomy alone). Targeted DNA sequencing and RNA expression of tumor foci and adjacent noncancer regions were analyzed in conjunction with pathologic changes and clinical outcomes.

Results</

SUBMITTER: Sumiyoshi T 

PROVIDER: S-EPMC10777679 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature